

Doxycycline Hyclate Capsules

Type of Posting	Revision Bulletin
Posting Date	28–April–2017
Official Date	01–May–2017
Expert Committee	Chemical Medicines Monographs 1
Reason for Revision	Compliance

In accordance with the Rules and Procedures of the 2015-2020 Council of Experts, the Chemical Medicines Monographs 1 Expert Committee has revised the Doxycycline Hyclate Capsules monograph. The purpose of the revision is to widen the limit for 4-epidoxycycline in the test for Organic Impurities from NMT 0.5% to 1.0% to accommodate the sponsor's FDA-approved specification.

The Doxycycline Hyclate Capsules Revision Bulletin supersedes the currently official monograph. The Revision Bulletin will be incorporated into *USP 41–NF 36*.

Should you have any questions, please contact Praveen Pabba (301–816–8540 or pkp@usp.org.)

Doxycycline Hyclate Capsules

DEFINITION

Doxycycline Hyclate Capsules contain the equivalent of NLT 90.0% and NMT 120.0% of the labeled amount of doxycycline (C₂₂H₂₄N₂O₈).

IDENTIFICATION

Delete the following:

▲ A.

Test solution: Nominally 1 mg/mL of doxycycline in methanol prepared from Capsule contents. Pass through a filter, and use the filtrate.

Analysis: Proceed as directed in *Identification—Tetracyclines* (193), *Method II*.

Acceptance criteria: Meet the requirement.▲USP40

Add the following:

▲ A. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.▲USP40

ASSAY

Change to read:

• PROCEDURE

▲Protect solutions containing doxycycline from light.

Solution A: Transfer 3.1 g of monobasic potassium phosphate, 0.5 g of edetate disodium, and 0.5 mL of triethylamine to a 1000-mL volumetric flask. Add about 850 mL of water and mix. Dilute with water to volume and adjust with 1 N sodium hydroxide to a pH of 8.5 ± 0.2.

Solution B: Methanol

Mobile phase: See *Table 1*.

Table 1

Time (min)	Solution A (%)	Solution B (%)
0.0	90	10
2.0	90	10
4.0	60	40
6.0	90	10
9.0	90	10

Diluent: 0.01 N hydrochloric acid

System suitability stock solution 1: 1 mg/mL each of USP Doxycycline Related Compound A RS and USP Methacycline Hydrochloride RS in *Diluent*

System suitability stock solution 2: 1.2 mg/mL of USP Doxycycline Hyclate RS in *Diluent*

System suitability solution: Transfer 5 mL of *System suitability stock solution 2* to a 25-mL volumetric flask, heat on a steam bath for 60 min, and evaporate to dryness on a hot plate, taking care not to char the residue. Dissolve the residue in *Diluent*, add 0.5 mL of *System suitability stock solution 1*, and dilute with *Diluent* to volume. Pass the solution through a suitable filter and use the filtrate.

This solution contains a mixture of 4-epidoxycycline, doxycycline related compound A, methacycline, and doxycycline. When stored in a refrigerator, this solution may be used for 14 days.

Standard solution: 0.3 mg/mL of USP Doxycycline Hyclate RS in *Diluent*. Sonicate as needed to dissolve.

Sample solution: Nominally 0.25 mg/mL of doxycycline in *Diluent*, prepared as follows. Empty as completely as possible the contents of NLT 20 Capsules. Mix the combined contents and transfer a suitable portion of the powder to a suitable volumetric flask. Add 75% of the final volume of *Diluent*, sonicate for about 5 min, shake for about 15 min, and dilute with *Diluent* to volume. Pass a portion of this solution through a suitable filter of 0.2-µm pore size.

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 350 nm

Column: 2.1-mm × 5-cm; 1.7-µm packing L7.

[NOTE—A 1.7-µm guard column with packing L7 was used during method validation.]

Column temperature: 60°

Flow rate: 0.6 mL/min

Injection volume: 5 µL

System suitability

Samples: *System suitability solution* and *Standard solution*

[NOTE—See *Table 2* for relative retention times.]

Suitability requirements

Resolution: NLT 1.5 between methacycline and 4-epidoxycycline; NLT 1.5 between 4-epidoxycycline and doxycycline related compound A; NLT 1.5 between doxycycline related compound A and doxycycline, *System suitability solution*

Tailing factor: NMT 1.5, *Standard solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of doxycycline (C₂₂H₂₄N₂O₈) in the portion of Capsules taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P \times F \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of USP Doxycycline Hyclate RS in the *Standard solution* (mg/mL)

C_U = nominal concentration of doxycycline in the *Sample solution* (mg/mL)

P = potency of doxycycline in USP Doxycycline Hyclate RS (µg/mg)

F = conversion factor, 0.001 mg/µg

Acceptance criteria: 90.0%–120.0%▲USP40

PERFORMANCE TESTS

Change to read:

• DISSOLUTION (711)

Medium: Water; 900 mL

Apparatus 2: 75 rpm, the distance between the blade and the inside bottom of the vessel being maintained at 4.5 ± 0.5 cm during the test

Time: 30 min

Standard solution: USP Doxycycline Hyclate RS in *Medium*

Sample solution: Sample per *Dissolution* (711). Dilute with *Medium* to a concentration that is similar to the *Standard solution*.

2 Doxycycline

Instrumental conditions

Mode: UV

Analytical wavelength: 276 nm

▲Analysis

Samples: *Standard solution* and *Sample solution*
Calculate the percentage of the labeled amount of doxycycline ($C_{22}H_{24}N_2O_8$) dissolved:

$$\text{Result} = (A_U/A_S) \times (C_S/L) \times V \times 100$$

A_U = absorbance of the *Sample solution*

A_S = absorbance of the *Standard solution*

C_S = concentration of doxycycline in the *Standard solution* (mg/mL)

L = label claim (mg/Capsule)

V = volume of *Medium*, 900 mL▲*USP40*

Tolerances: NLT 80% (Q) of the labeled amount of doxycycline ($C_{22}H_{24}N_2O_8$) is dissolved.

- **UNIFORMITY OF DOSAGE UNITS <905>:** Meet the requirements

IMPURITIES

Change to read:

▲• ORGANIC IMPURITIES

Mobile phase, Diluent, System suitability solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay.

Standard solution: 1.5 µg/mL of USP Doxycycline Hyclate RS in Diluent

System suitability

Samples: *System suitability solution* and *Standard solution*

Suitability requirements

Resolution: NLT 1.5 between methacycline and 4-epidoxycycline; NLT 1.5 between 4-epidoxycycline and doxycycline related compound A; NLT 1.5 between doxycycline related compound A and doxycycline, *System suitability solution*

Relative standard deviation: NMT 5.0% for the doxycycline peak, *Standard solution*

Analysis

Samples: *Sample solution* and *Standard solution*
Calculate the percentage of each impurity in the portion of Capsules taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P \times F \times 100$$

r_U = peak response of each impurity from the *Sample solution*

r_S = peak response of doxycycline from the *Standard solution*

C_S = concentration of USP Doxycycline Hyclate RS in the *Standard solution* (mg/mL)

C_U = nominal concentration of doxycycline in the *Sample solution* (mg/mL)

P = potency of doxycycline in USP Doxycycline Hyclate RS (µg/mg)

F = conversion factor, 0.001 mg/µg

Acceptance criteria: See Table 2. Disregard any impurity peaks less than 0.2%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Methacycline ^{a,b}	0.64	—
4-Epidoxycycline ^c	0.79	1.0 (RB 1-May-2017)
Doxycycline related compound A (6-epidoxycycline) ^{a,d}	0.88	—
Doxycycline	1.0	—
Any individual unspecified impurity	—	0.5
Total impurities	—	2.0

^a Process impurities are controlled in the drug substance and are not to be reported here. They are not included in total impurities.

^b (4*S*,4*aR*,5*S*,5*aR*,12*aS*)-4-(Dimethylamino)-1,4,4*a*,5,5*a*,6,11,12*a*-octahydro-3,5,10,12,12*a*-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide.

^c (4*R*,4*aR*,5*S*,5*aR*,6*R*,12*aS*)-4-(Dimethylamino)-1,4,4*a*,5,5*a*,6,11,12*a*-octahydro-3,5,10,12,12*a*-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide.

^d (4*S*,4*aR*,5*S*,5*aR*,6*S*,12*aS*)-4-(Dimethylamino)-1,4,4*a*,5,5*a*,6,11,12*a*-octahydro-3,5,10,12,12*a*-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide.

▲*USP40*

SPECIFIC TESTS

Delete the following:

- ▲• **WATER DETERMINATION, Method I <921>:** NMT 8.5%▲*USP40*

ADDITIONAL REQUIREMENTS

Change to read:

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers. ▲Store at controlled room temperature.▲*USP40*

Change to read:

- **USP REFERENCE STANDARDS <11>**
USP Doxycycline Hyclate RS
▲USP Doxycycline Related Compound A RS. [NOTE—May be available as a free base or a hydrochloride salt.]
(4*S*,4*aR*,5*S*,5*aR*,6*S*,12*aS*)-4-(Dimethylamino)-1,4,4*a*,5,5*a*,6,11,12*a*-octahydro-3,5,10,12,12*a*-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide.
 $C_{22}H_{24}N_2O_8$ 444.43
(4*S*,4*aR*,5*S*,5*aR*,6*S*,12*aS*)-4-(Dimethylamino)-1,4,4*a*,5,5*a*,6,11,12*a*-octahydro-3,5,10,12,12*a*-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide, monohydrochloride.
 $C_{22}H_{24}N_2O_8 \cdot HCl$ 480.13
USP Methacycline Hydrochloride RS▲*USP40*